Double-Drug attack on tough pancreatic cancer shows promise in small trial
NCT ID NCT05068752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two oral chemotherapy drugs, vemurafenib and sorafenib, in 10 people with advanced pancreatic cancer that has a specific genetic change called a KRAS mutation. All participants had already tried at least two standard treatments without success. The main goal was to see if the drug combination could control the cancer for at least 16 weeks. The approach targets a key signaling pathway in cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States